Sonidegib is an antineoplastic agent used for the treatment of locally advanced recurrent basal cell carcinoma (BCC) following surgery and radiation therapy, or in cases where surgery or radiation therapy are not appropriate. Sonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis.
- Mechanism
- Curator reviewed
The hedgehog pathway is involved in many human cancers. Sonidegib effectively inhibits the regulator called smoothened (Smo), preventing the hedgehog pathway from functioning. As a result, tumours that depend on the hedgehog pathway are unable to grow. (1)
- Primary indication
- Sonidegib is approved for use in the US and EU for treatment of adults with locally advanced basal cell carcinoma (BCC) that has recurred post surgery or radiation therapy.Curator reviewed · 1 structured indication
- Formula / weight
- C26H26F3N3O3 · 485.507 g/mol (avg)
- First approval
- Canada, 2022 · United States, 2015 · European Union, 2016
- Also known as
- Erismodegib
- Code names
- LDE-225 · NVP-LDE 225
- Brand names
Resolves to
VZZJRYRQSPEMTK-CALCHBBNSA-NSMILES[H][C@]1(C)CN(C[C@@]([H])(C)O1)C1=CC=C(NC(=O)C2=CC=CC(=C2C)C2=CC=C(OC(F)(F)F)C=C2)C=N1What you can answer from here — as of September 23, 2026
Which drugs share a target with Sonidegib, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account